The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
miRNA nanotherapeutics for cancer
Open accessAbstract
miRNAs are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
Cationic polymers and their therapeutic potential
Samal, S. K., Dash, M., Van Vlierberghe, S., Kaplan, D. L., Chiellini, E., van Blitterswijk, C., Moroni, L., & Dubruel, P. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35094g · Cited by 714
Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.013 · Cited by 626
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 511
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Therapeutic Applications of Curcumin Nanoformulations
Yallapu, M. M., Nagesh, P. K. B., Jaggi, M., & Chauhan, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9811-z · Cited by 392
Self-citationHola, K., Markova, Z., Zoppellaro, G., Tucek, J., & Zboril, R. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.003 · Cited by 372
Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K., & Richer, J. K. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1046 · Cited by 320
Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
Juliano, R., Bauman, J., Kang, H., & Ming, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900093r · Cited by 304
Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer
Yallapu, M. M., Khan, S., Maher, D. M., Ebeling, M. C., Sundram, V., Chauhan, N., Ganju, A., Balakrishna, S., Gupta, B. K., Zafar, N., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.040 · Cited by 290
Self-citationMacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
Devulapally, R., Sekar, N. M., Sekar, T. V., Foygel, K., Massoud, T. F., Willmann, J. K., & Paulmurugan, R. (2015) · ACS Nano · doi:10.1021/nn507465d · Cited by 260
Small RNA combination therapy for lung cancer
Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412686111 · Cited by 242
Hwang, D. W., Son, S., Jang, J., Youn, H., Lee, S., Lee, D., Lee, Y.-S., Jeong, J. M., Kim, W. J., & Lee, D. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.047 · Cited by 234
Tivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fernández, R., Bray, I. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038129 · Cited by 233
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer
Wu, Y., Crawford, M., Mao, Y., Lee, R. J., Davis, I. C., Elton, T. S., Lee, L. J., & Nana-Sinkam, S. P. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.14 · Cited by 223
MicroRNAs and Metastasis: Little RNAs Go a Long Way
Dykxhoorn, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1346 · Cited by 210
Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2010) · The Prostate · doi:10.1002/pros.21185 · Cited by 205
Pang, Y., Wang, C., Wang, J., Sun, Z., Xiao, R., & Wang, S. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.12.052 · Cited by 203
Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer
Cortez, M. A., Valdecanas, D., Zhang, X., Zhan, Y., Bhardwaj, V., Calin, G. A., Komaki, R., Giri, D. K., Quini, C. C., Wolfe, T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.79 · Cited by 196
Huang, X., Schwind, S., Yu, B., Santhanam, R., Wang, H., Hoellerbauer, P., Mims, A., Klisovic, R., Walker, A. R., Chan, K. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3191 · Cited by 193
Targeting of miR34a–NOTCH1 Axis Reduced Breast Cancer Stemness and Chemoresistance
Park, E. Y., Chang, E., Lee, E. J., Lee, H.-W., Kang, H.-G., Chun, K.-H., Woo, Y. M., Kong, H. K., Ko, J. Y., Suzuki, H., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1140 · Cited by 188
Costa, P. M., Cardoso, A. L., Custódia, C., Cunha, P., Pereira de Almeida, L., & Pedroso de Lima, M. C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.002 · Cited by 187
Qian, X., Long, L., Shi, Z., Liu, C., Qiu, M., Sheng, J., Pu, P., Yuan, X., Ren, Y., & Kang, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.039 · Cited by 186
Wang, S., Zhang, J., Wang, Y., & Chen, M. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.014 · Cited by 186
Ren, Y., Kang, C.-S., Yuan, X.-B., Zhou, X., Xu, P., Han, L., Wang, G. X., Jia, Z., Zhong, Y., Yu, S., et al. (2010) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856209x415828 · Cited by 175
A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells
Ghosh, R., Singh, L. C., Shohet, J. M., & Gunaratne, P. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.023 · Cited by 172
Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy
Esposito, C. L., Cerchia, L., Catuogno, S., De Vita, G., Dassie, J. P., Santamaria, G., Swiderski, P., Condorelli, G., Giangrande, P. H., & de Franciscis, V. (2014) · Molecular Therapy · doi:10.1038/mt.2014.5 · Cited by 169
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Daige, C. L., Wiggins, J. F., Priddy, L., Nelligan-Davis, T., Zhao, J., & Brown, D. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0209 · Cited by 168
Zhi, F., Dong, H., Jia, X., Guo, W., Lu, H., Yang, Y., Ju, H., Zhang, X., & Hu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060034 · Cited by 164
Ma, S., Tian, X. Y., Zhang, Y., Mu, C., Shen, H., Bismuth, J. X., Pownall, H. J., Huang, Y., & Wong, W. T. (2016) · Scientific Reports · doi:10.1038/srep22910 · Cited by 163
Mittal, A., Chitkara, D., Behrman, S. W., & Mahato, R. I. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.053 · Cited by 161
Self-citationNanoparticles containing insoluble drug for cancer therapy
Guo, S., & Huang, L. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.10.002 · Cited by 159
CD4 + CD25 + regulatory T cells in tumor immunity
Chen, X., Du, Y., Lin, X., Qian, Y., Zhou, T., & Huang, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.03.009 · Cited by 159
Shi, S., Han, L., Deng, L., Zhang, Y., Shen, H., Gong, T., Zhang, Z., & Sun, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.005 · Cited by 158
Bertucci, A., Prasetyanto, E. A., Septiadi, D., Manicardi, A., Brognara, E., Gambari, R., Corradini, R., & Cola, L. D. (2015) · Small · doi:10.1002/smll.201500540 · Cited by 150
Dai, X., & Tan, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.010 · Cited by 149
Cubillos‐Ruiz, J. R., Baird, J. R., Tesone, A. J., Rutkowski, M. R., Scarlett, U. K., Camposeco-Jacobs, A. L., Anadon-Arnillas, J., Harwood, N. M., Korc, M., Fiering, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3160 · Cited by 149
Gaur, S., Wen, Y., Song, J. H., Parikh, N. U., Mangala, L. S., Blessing, A. M., Ivan, C., Wu, S. Y., Varkaris, A. S., Shi, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4971 · Cited by 138
MicroRNAs in colorectal carcinoma - from pathogenesis to therapy
Chi, Y., & Zhou, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0320-4 · Cited by 127
Gao, S., Tian, H., Guo, Y., Li, Y., Guo, Z., Zhu, X., & Chen, X. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.07.020 · Cited by 123
Liu, Q., Li, R., Qian, H., Wei, J., Li, X., Shen, J., Yang, M., Qian, X., Yu, L., Jiang, X., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.004 · Cited by 123
Hu, Q., Jiang, Q., Jin, X., Shen, J., Wang, K., Li, Y. B., Xu, F., Tang, G., & Li, Z. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.016 · Cited by 116
Alhasan, A. H., Patel, P. C., Choi, C. H. J., & Mirkin, C. A. (2013) · Small · doi:10.1002/smll.201302143 · Cited by 111
Liu, X., Song, W., Sun, T., Zhang, P., & Wang, J. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100315q · Cited by 109
MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer
Khan, S., Ebeling, M. C., Zaman, M. S., Sikander, M., Yallapu, M. M., Chauhan, N., Yacoubian, A. M., Behrman, S. W., Zafar, N., Kumar, D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2281 · Cited by 105
Self-citationChen, W., Liu, S.-Y., Chang, Y.-S., Yin, J. J., Yeh, H.-L., Mouhieddine, T. H., Hadadeh, O., Abou-Kheir, W. G., & Liu, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2690 · Cited by 99
Huang, Z. D., Gan, J., Long, Z., Guo, G., Shi, X., Wang, C., Zang, Y., Ding, Z., Chen, J., Zhang, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.009 · Cited by 99
Conde, J., Rosa, J., de la Fuente, J. M., & Baptista, P. V. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.015 · Cited by 97
Porru, M., Zappavigna, S., Salzano, G., Luce, A., Stoppacciaro, A., Balestrieri, M. L., Artuso, S., Lusa, S., Rosa, G. D., Leonetti, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2182 · Cited by 93
Zhang, M., Zhou, X., Wang, B., Yung, B. C., Lee, L. J., Ghoshal, K., & Lee, R. J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.020 · Cited by 93
Xu, Q., Li, P., Chen, X., Zong, L., Jiang, Z., Nan, L., Lei, J., Duan, W., Zhang, D., Li, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3686 · Cited by 90
Kim, E., Yang, J., Park, J., Kim, S., Kim, N. H., Yook, J. I., Suh, J., Haam, S., & Huh, Y. (2012) · ACS Nano · doi:10.1021/nn300289u · Cited by 88
RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis
Heman-Ackah, S. M., Hallegger, M., Rao, M. S., & Wood, M. J. A. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00040 · Cited by 87
Xiao, Z., Li, C. H., Chan, S. L., Xu, F., Lu, F., Wang, Y., Jiang, J.-D., Sung, J. J. �., Cheng, C. H. K., & Chen, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0855 · Cited by 86
miRNA profiling in pancreatic cancer and restoration of chemosensitivity
Singh, S. P., Chitkara, D., Kumar, V., Behrman, S. W., & Mahato, R. I. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.008 · Cited by 83
Self-citationDevalliere, J., Chang, W. G., Andrejecsk, J. W., Abrahimi, P., Cheng, C. J., Jane‐wit, D., Saltzman, W. M., & Pober, J. S. (2014) · The FASEB Journal · doi:10.1096/fj.13-238527 · Cited by 83
A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA
Zhang, T., Xue, X., He, D., & Hsieh, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.003 · Cited by 80
Ou, H., Li, Y., & Kang, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109929 · Cited by 79
Park, J., Lee, J., Kwag, J., Baek, Y., Kim, B., Yoon, C. J., Bok, S., Cho, S., Kim, K. H., Ahn, G., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b02357 · Cited by 79
Innovative Strategy for MicroRNA Delivery in Human Mesenchymal Stem Cells via Magnetic Nanoparticles
Schade, A., Delyagina, E., Scharfenberg, D., Skorska, A., Lux, C. A., David, R., & Steinhoff, G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140610710 · Cited by 76
Naltrexone: A review of existing sustained drug delivery systems and emerging nano-based systems
Goonoo, N., Bhaw‐Luximon, A., Ujoodha, R., Jhugroo, A., Hulse, G. K., & Jhurry, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.046 · Cited by 75
Singh, A. P., Arora, S., Swaminathan, S. K., Kirtane, A. R., Srivastava, S., Bhardwaj, A., Singh, S., & Panyam, J. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61949 · Cited by 74
Ananta, J. S., Paulmurugan, R., & Massoud, T. F. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00694 · Cited by 74
Bhargava-Shah, A., Foygel, K., Devulapally, R., & Paulmurugan, R. (2016) · Nanomedicine · doi:10.2217/nnm.15.193 · Cited by 70
Liu, X., Li, G., Su, Z., Jiang, Z., Chen, L., WANG, J., Yu, S., & LIU, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2283 · Cited by 66
Wang, X., Huang, X., Yang, Z., Gallego‐Perez, D., Ma, J., Zhao, X., Xie, J., Nakano, I., & Lee, L. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666141031105234 · Cited by 65
Dual MMP7-Proximity-Activated and Folate Receptor-Targeted Nanoparticles for siRNA Delivery
Li, H., Miteva, M., Kirkbride, K. C., Cheng, M. J., Nelson, C. E., Simpson, E. M., Gupta, M. K., Duvall, C. L., & Giorgio, T. D. (2014) · Biomacromolecules · doi:10.1021/bm501394m · Cited by 64
Sun, Z., Song, X., Li, X., Su, T., Qi, S., Qiao, R., Wang, F., Huan, Y., Yang, W., Wang, J., et al. (2014) · Nanoscale · doi:10.1039/c4nr03003f · Cited by 62
Seviour, E. G., Sehgal, V., Lu, Y., Luo, Z., Moss, T. J. M., Zhang, F., Hill, S. M., Liu, W., Maiti, S. N., Cooper, L. J. N., et al. (2015) · Oncogene · doi:10.1038/onc.2014.469 · Cited by 52
Chien, Y., Chang, Y.-L., Li, H.-Y., Larsson, M., Wu, W.-W., Chien, C., Wang, C., Chu, P., Chen, K.-H., Lo, W., et al. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.11.018 · Cited by 47
MicroRNAs in sensorineural diseases of the ear
Ushakov, K., Rudnicki, A., & Avraham, K. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00052 · Cited by 43
Wu, Y., Ma, J., Woods, P. S., Chesarino, N. M., Liu, C., Lee, L. J., Nana-Sinkam, S. P., & Davis, I. C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.016 · Cited by 40
MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt
Yang, W., Yang, Y., Xia, L., Yang, Y., Wang, F., Song, M., Chen, X., Liu, J., Song, Y., Zhao, Y., et al. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445589 · Cited by 40
Chung, W.-M., Chang, W.-C., Chen, L., Chang, Y.-Y., Shyr, C., Hung, Y., & Ma, W. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt247 · Cited by 38
Yu, Y., Yao, Y., Yan, H., Wang, R., Zhang, Z., Sun, X., Zhao, L., Ao, X., Xie, Z., & Wu, Q. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.28 · Cited by 31
Pan, F., Mao, H., Deng, L., Li, G., & Geng, P. (2014) · PubMed · Cited by 27
Lellouche, E., Israel, L. L., Bechor, M., Attal, S., Kurlander, E., Asher, V. A., Dolitzky, A., Shaham, L., Izraeli, S., Lellouche, J., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00276 · Cited by 24
PEI-complexed LNA antiseeds as miRNA inhibitors
Thomas, M., Lange-Grünweller, K., Dayyoub, E., Bakowsky, U., Weirauch, U., Aigner, A., Hartmann, R. K., & Grünweller, A. (2012) · RNA Biology · doi:10.4161/rna.21165 · Cited by 22
Cheng, R.-F., Wang, J., Zhang, J.-Y., Sun, L., Zhao, Y., Qiu, Z., Sun, B., & Sun, Y. (2016) · 癌症:英文版 · doi:10.1186/s40880-016-0128-9 · Cited by 21
Cited by
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
Salemi, M., Mogavero, M. P., Lanza, G., Mongioì, L. M., Calogero, A. E., & Ferri, R. (2022) · Cells · doi:10.3390/cells11121930 · Cited by 39
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32
RetractedRoles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development
Hwang, G.-R., Yuen, J. G., & Ju, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041624 · Cited by 15
Metadata
- Authors
- Ganju, A., Khan, S., Hafeez, B. B., Behrman, S. W., Yallapu, M. M., Chauhan, S. C., & Jaggi, M.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 22
- Issue
- 2
- Pages
- 424-432
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2548805615
- Cited by
- 298
- References
- 83
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.